Platform Launch CircPATH platform launch, anchored by a Nature Medicine study validating early detection performance in Alzheimer's, provides a credible entry point for neurology and psychiatry diagnostics. This creates sales opportunities for licensing CircPATH, enterprise pilots with hospitals and research consortia, and integration into existing care workflows.

Strategic Partnerships Strategic partnerships with the Global Alzheimer's Platform Foundation, Decode Health, and Vitazi.ai extend Circular Genomics' market access into large-scale studies, MS biomarker programs, and AI-enabled analytics. These collaborations provide ready-made use cases and networks to target pharma sponsors, CROs, and health systems for early-detection and monitoring solutions.

Multimodal Advantage Development of a multimodal workflow that combines circular RNA biomarkers with AI-based analytics positions Circular Genomics to offer integrated diagnostic solutions for early Alzheimer's detection and risk stratification. This enables cross-sell opportunities within neurology clinics, specialty hospitals, and research centers seeking end-to-end workflows.

Growth Credibility Strong financial backing and seasoned scientific leadership elevate confidence in pursuing larger enterprise deals and widespread clinical validation. A capable funding environment and an influential advisory board support scaled sales efforts, partnerships, and multi-site studies.

Targeted Customers Clear focus on precision neurology and psychiatry with assays that tailor patient management creates compelling use cases for pharma sponsors, hospitals, clinics, and research institutions looking to improve early identification and individualized care pathways.